Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.
Stocks · News reference
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Edges Higher; Citigroup Earnings Top Views
U.S. stocks edged lower; Citi beat Q3 estimates. Bumble and BIO-key surged, while Pershing Square, Cipher Digital and Syndax fell.
Syndax Pharmaceuticals shares are trading lower after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.